Aro Biotherapeutics
Philadelphia, US · Founded 2017 · Delaware corporation · 7 known investors
Find your way into Aro Biotherapeutics
42 people in our graph share verified history with the Aro Biotherapeutics team — schools, employers, funds. One of them is your warm intro.
Steve Liapisunlockedknows Susan Dillon · together at Aro Biotherapeutics (overlapped)
×2knows the team · via Duke University School of Medicine
knows the team · via Aro Biotherapeutics
knows the team · via Temple University - Lewis Katz School of Medicine
×5knows the team · via Jefferson Health
×2knows the team · via Buffalo State University
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Founders & leadership
Aro Biotherapeutics was founded in 2017 by Karyn O'Neil and Susan Dillon.
KO
Karyn O'NeilCo-founder
SD
Susan DilloninCo-founder · Board ChairSusan Dillon earned a Ph.D. in Microbiology and Immunology from Thomas Jefferson University and completed a postdoctoral fellowship in Immunology at Duke University. She held multiple leadership roles at Centocor and Janssen Research & Development from 2001 to 2017, including Global Therapeutic Area Head for immunology, overseeing discovery and development of immunology therapeutics, before co-founding Aro Biotherapeutics.
MV
Mark V. LaurenziNamed on SEC filing
Board
EA
Elizabeth AndersonBoard director
BP
Investors · 7
Funding
SEC filings, press & company announcements$164.4M disclosed across 5 rounds · 2019–2023
- $41.5MSeries BNov 2023 · 2 sources
Cowen Healthcare Investments (lead), BVF Partners, Healthcap, Johnson & Johnson Innovation – JJDC, Northpond Ventures
Source ↗
▶$24MraisedDec 2022 · 12 investors · PharmaceuticalsRule 506(b)
▶$24MraisedDec 2022 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher MirabelliDirector
- Susan B DillonExecutive Officer, Director
- Scott GreenbergExecutive Officer
- Karyn O'NeilExecutive Officer, Director
- Marten SteenDirector
- Bruce PeacockDirector
- Elizabeth AndersonDirector
- Daniel JanseDirector
- Mark LaurenziExecutive Officer
- Kevin RaidyDirector
- Mittie DoyleExecutive Officer
- Offering amount
- $100M
- Amount sold
- $24M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$90.3MraisedDec 2021 · 14 investors · PharmaceuticalsRule 506(b)
▶$90.3MraisedDec 2021 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott GreenbergExecutive Officer
- Jess LiftonDirector
- Marten SteenDirector
- Kevin RaidyDirector
- Christopher MirabelliDirector
- Daniel JanseDirector
- Elizabeth AndersonDirector
- Mark LaurenziExecutive Officer
- Karyn O'NeilExecutive Officer, Director
- Susan B DillonExecutive Officer, Director
- Bruce PeacockDirector
- Offering amount
- $90.3M
- Amount sold
- $90.3M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5MraisedJan 2020 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedJan 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce PeacockDirector
- Mark LaurenziExecutive Officer
- Karyn O'NeilExecutive Officer, Director
- Susan B DillonExecutive Officer, Director
- Elizabeth AndersonDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.5MraisedApr 2019 · 3 investors · BiotechnologyRule 506(b)
▶$3.5MraisedApr 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Susan B DillonExecutive Officer, Director
- Karyn O'NeilExecutive Officer, Director
- Mark V. LaurenziExecutive Officer
- Elizabeth AndersonDirector
- Bruce PeacockDirector
- Offering amount
- $4.9M
- Amount sold
- $3.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Aro Biotherapeutics do?
- Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
- Who founded Aro Biotherapeutics?
- Aro Biotherapeutics was founded by Karyn O'Neil, Susan Dillon in 2017.
- Who are Aro Biotherapeutics's investors?
- Aro Biotherapeutics's investors include Avego BioScience Capital, HealthCap, Agent Capital, Biotechnology Value Fund, Cowen Healthcare Investments, Johnson & Johnson Innovation – JJDC, Northpond Ventures.
- How much funding has Aro Biotherapeutics raised?
- Aro Biotherapeutics has disclosed $164.4M raised across 5 rounds.
- Where is Aro Biotherapeutics headquartered?
- Aro Biotherapeutics is headquartered in Philadelphia, US.